Clinical trials: Epithelioid Mesothelioma, active
Pleural Mesothelioma, Mesothelioma
A Phase 3 Trial in Advanced Epithelioid Mesothelioma
This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior…
- Trial name
- sTEADfast (NCT07824986)
- Testing
- VT3989, gemcitabine, Vinorelbine
- Volunteers
- 350 people
- Sponsor
- Vivace Therapeutics, Inc
Pleural Mesothelioma
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
This is a prospective, open-label, multi-site Phase II trial of pembrolizumab in combination with pemetrexed and cisplatin or carboplatin as neo-adjuvant therapy followed by surgery and adjuvant pembrolizumab in patients affected…
- Trial name
- CHIMERA (NCT06155279)
- Testing
- Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
- Where
- 8 sites in Italy
- Volunteers
- 41 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Malignant Pleural Mesothelioma
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into…
- Trial name
- Immuno-MESODEC (NCT05765084)
- Testing
- Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 15 people
- Sponsor
- University Hospital, Antwerp
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural…
- Conditions
- Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
- Trial name
- NCT01064648
- Testing
- Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis
- Where
- 230 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
Biphasic Mesothelioma, Epithelioid Mesothelioma
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma.
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
- Trial name
- NCT03228537
- Testing
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy
- Where
- 174 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
The goal of this clinical trial is to evaluate whether a combination of chemotherapy and immunotherapy can make surgery possible in adults with inoperable pleural mesothelioma (a type of cancer affecting the lung lining).
- Conditions
- Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura, Neoadjuvant Chemoimmunotherapy
- Trial name
- NECIM (NCT07121374)
- Testing
- Neoadjuvant chemo-immunotherapy, Extended pleurectomy/decortication in case of reaching operability
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- University Hospital, Antwerp
Mesothelioma, Epithelioid Hemangioendothelioma(EHE)
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in…
- Conditions
- Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
- Trial name
- NCT06452160
- Testing
- BGC515
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- BridGene Biosciences Inc.